|Dr. Reddy is available at a steep 35% discount to the sector average valuation|
Lupin and Sun Pharma trade at premiums to the sector average valuation
It seems there is higher premium to companies with better near term growth prospects. Lupin and Sun's growth in the near term will be supported by high value generic launches (gGlivec and gGlumetza) under 180-days exclusivity.